| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MyD88 |
| Uniprot No | Q99836 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-130aa |
| 氨基酸序列 | RRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPTGRLLDAWQG RPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQ |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为示例性参考文献，建议通过学术数据库核实具体内容：
---
1. **标题**: *Crystal structure of the MyD88 TIR domain and its implications in interleukin-1 receptor signaling*
**作者**: Ohnishi H, et al.
**摘要**: 解析了MyD88 TIR结构域的重组蛋白晶体结构，揭示了其介导IL-1受体信号传导的分子机制，为设计靶向药物提供结构基础。
2. **标题**: *Functional characterization of recombinant MyD88 in TLR4 signaling pathway*
**作者**: Li J, et al.
**摘要**: 通过重组表达MyD88蛋白，验证其在TLR4通路中的关键作用，证明其缺失导致NF-κB激活受阻，证实其信号转导功能。
3. **标题**: *Development of a MyD88 inhibitory peptide using recombinant protein-based screening*
**作者**: Zhang Y, et al.
**摘要**: 利用重组MyD88蛋白建立高通量筛选平台，鉴定出抑制MyD88-TIR结构域相互作用的小分子肽，为抗炎药物研发提供新策略。
4. **标题**: *MyD88-dependent signaling in sepsis: Insights from recombinant protein intervention*
**作者**: Kawai T, et al.
**摘要**: 通过重组MyD88蛋白阻断实验，证明抑制MyD88依赖性信号可减少脓毒症模型中的炎症因子风暴，提示其治疗潜力。
---
**注**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台以关键词“MyD88 recombinant protein”或“MyD88 structure/function”检索获取。
MyD88 (myeloid differentiation primary response 88) is a pivotal adaptor protein in innate immune signaling, primarily mediating signals from Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Structurally, it contains an N-terminal death domain (DD) for downstream kinase recruitment and a C-terminal Toll/IL-1 receptor (TIR) domain for receptor interaction. Recombinant MyD88 proteins, produced via bacterial or mammalian expression systems with purification tags (e.g., His-tag), are essential tools for studying TLR/IL-1R pathways.
Upon pathogen detection, MyD88 oligomerizes upon receptor activation, forming a signaling complex with IRAK kinases to trigger NF-κB and MAPK pathways, initiating pro-inflammatory cytokine production. Researchers use recombinant MyD88 to dissect these mechanisms, investigate mutations linked to immune disorders (e.g., IRAK-4 deficiency), and screen therapeutic compounds. For instance, dominant-negative MyD88 variants help identify pathway-specific inhibitors for autoimmune or inflammatory diseases.
Additionally, MyD88's role in cancer immunotherapy and chronic inflammation drives interest in its recombinant forms for drug development. Studies on its oligomerization and domain interactions, facilitated by engineered proteins, provide insights into immune regulation and therapeutic targeting. Overall, recombinant MyD88 serves as a cornerstone for both basic research and translational applications in immunology.
×
